| pubmed-article:10557052 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10557052 | lifeskim:mentions | umls-concept:C0017296 | lld:lifeskim |
| pubmed-article:10557052 | lifeskim:mentions | umls-concept:C0007634 | lld:lifeskim |
| pubmed-article:10557052 | lifeskim:mentions | umls-concept:C0870134 | lld:lifeskim |
| pubmed-article:10557052 | lifeskim:mentions | umls-concept:C0037993 | lld:lifeskim |
| pubmed-article:10557052 | lifeskim:mentions | umls-concept:C0007257 | lld:lifeskim |
| pubmed-article:10557052 | lifeskim:mentions | umls-concept:C0600688 | lld:lifeskim |
| pubmed-article:10557052 | lifeskim:mentions | umls-concept:C1545588 | lld:lifeskim |
| pubmed-article:10557052 | lifeskim:mentions | umls-concept:C0681842 | lld:lifeskim |
| pubmed-article:10557052 | lifeskim:mentions | umls-concept:C1171947 | lld:lifeskim |
| pubmed-article:10557052 | lifeskim:mentions | umls-concept:C1513327 | lld:lifeskim |
| pubmed-article:10557052 | lifeskim:mentions | umls-concept:C0591833 | lld:lifeskim |
| pubmed-article:10557052 | pubmed:issue | 11 | lld:pubmed |
| pubmed-article:10557052 | pubmed:dateCreated | 1999-12-7 | lld:pubmed |
| pubmed-article:10557052 | pubmed:abstractText | The effect of expression of an O6-benzylguanine (O6-beG)-resistant mutant (hATPA/GA) of human O6-alkylguanine-DNA alkyltransferase (ATase) on the in vivo toxicity and clastogenicity of the anti-tumour agent N,N'-bis(2-chloroethyl)-N-nitrosourea (BCNU) to murine bone marrow has been investigated. When compared with control animals, the bipotent granulocyte-macrophage colony-forming (GM-CFC) progenitor population of the hATPA/GA transduced mice were somewhat more resistant to BCNU (1.4-fold, P = 0.047) and this effect was more significant in the presence of the ATase inactivator O6-beG (3. 5-fold, P = 0.001). The polychromatic erythrocytes were also significantly protected against BCNU-induced clastogenicity both in the presence (P < 0.001) and absence of O6-beG (P < 0.05). The primitive, multipotent spleen colony-forming cells (CFU-S) in these animals also showed moderate (1.6-fold, P = 0.034) protection in the absence of O6-beG but in the presence of the inactivator they remained as sensitive to BCNU toxicity as those in the control animals (P = 0.133). This result contrasts with previous findings demonstrating significant hATPA/GA-mediated, O6-beG-resistant protection against the toxicity and clastogenicity of a number of O6-alkylating agents, including temozolomide, fotemustine and chlorozotocin. The possibility that our strategy for protective gene therapy may be highly agent and cell-type specific is unexpected and has possible implications for clinical trials of this approach using BCNU or related agents. | lld:pubmed |
| pubmed-article:10557052 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10557052 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10557052 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10557052 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10557052 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10557052 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10557052 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10557052 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10557052 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10557052 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10557052 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10557052 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:10557052 | pubmed:issn | 0887-6924 | lld:pubmed |
| pubmed-article:10557052 | pubmed:author | pubmed-author:RaffertyJJ | lld:pubmed |
| pubmed-article:10557052 | pubmed:author | pubmed-author:ThatcherNN | lld:pubmed |
| pubmed-article:10557052 | pubmed:author | pubmed-author:FairbairnLL | lld:pubmed |
| pubmed-article:10557052 | pubmed:author | pubmed-author:MargisonGG | lld:pubmed |
| pubmed-article:10557052 | pubmed:author | pubmed-author:LashfordLL | lld:pubmed |
| pubmed-article:10557052 | pubmed:author | pubmed-author:ChinnasamyNN | lld:pubmed |
| pubmed-article:10557052 | pubmed:author | pubmed-author:DexterTT | lld:pubmed |
| pubmed-article:10557052 | pubmed:author | pubmed-author:ChinnasamyDD | lld:pubmed |
| pubmed-article:10557052 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10557052 | pubmed:volume | 13 | lld:pubmed |
| pubmed-article:10557052 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10557052 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10557052 | pubmed:pagination | 1776-83 | lld:pubmed |
| pubmed-article:10557052 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:10557052 | pubmed:meshHeading | pubmed-meshheading:10557052... | lld:pubmed |
| pubmed-article:10557052 | pubmed:meshHeading | pubmed-meshheading:10557052... | lld:pubmed |
| pubmed-article:10557052 | pubmed:meshHeading | pubmed-meshheading:10557052... | lld:pubmed |
| pubmed-article:10557052 | pubmed:meshHeading | pubmed-meshheading:10557052... | lld:pubmed |
| pubmed-article:10557052 | pubmed:meshHeading | pubmed-meshheading:10557052... | lld:pubmed |
| pubmed-article:10557052 | pubmed:meshHeading | pubmed-meshheading:10557052... | lld:pubmed |
| pubmed-article:10557052 | pubmed:meshHeading | pubmed-meshheading:10557052... | lld:pubmed |
| pubmed-article:10557052 | pubmed:meshHeading | pubmed-meshheading:10557052... | lld:pubmed |
| pubmed-article:10557052 | pubmed:meshHeading | pubmed-meshheading:10557052... | lld:pubmed |
| pubmed-article:10557052 | pubmed:meshHeading | pubmed-meshheading:10557052... | lld:pubmed |
| pubmed-article:10557052 | pubmed:meshHeading | pubmed-meshheading:10557052... | lld:pubmed |
| pubmed-article:10557052 | pubmed:meshHeading | pubmed-meshheading:10557052... | lld:pubmed |
| pubmed-article:10557052 | pubmed:meshHeading | pubmed-meshheading:10557052... | lld:pubmed |
| pubmed-article:10557052 | pubmed:meshHeading | pubmed-meshheading:10557052... | lld:pubmed |
| pubmed-article:10557052 | pubmed:meshHeading | pubmed-meshheading:10557052... | lld:pubmed |
| pubmed-article:10557052 | pubmed:meshHeading | pubmed-meshheading:10557052... | lld:pubmed |
| pubmed-article:10557052 | pubmed:meshHeading | pubmed-meshheading:10557052... | lld:pubmed |
| pubmed-article:10557052 | pubmed:meshHeading | pubmed-meshheading:10557052... | lld:pubmed |
| pubmed-article:10557052 | pubmed:meshHeading | pubmed-meshheading:10557052... | lld:pubmed |
| pubmed-article:10557052 | pubmed:meshHeading | pubmed-meshheading:10557052... | lld:pubmed |
| pubmed-article:10557052 | pubmed:meshHeading | pubmed-meshheading:10557052... | lld:pubmed |
| pubmed-article:10557052 | pubmed:meshHeading | pubmed-meshheading:10557052... | lld:pubmed |
| pubmed-article:10557052 | pubmed:year | 1999 | lld:pubmed |
| pubmed-article:10557052 | pubmed:articleTitle | Protection of committed murine haemopoietic progenitors against BCNU toxicity does not predict protection of primitive, multipotent spleen colony-forming cells - implications for chemoprotective gene therapy. | lld:pubmed |
| pubmed-article:10557052 | pubmed:affiliation | CRC Sections of Genome Damage and Repair, Paterson Institute for Cancer Research, Manchester, UK. | lld:pubmed |
| pubmed-article:10557052 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10557052 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
